Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 854

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 854
---
) royalty revenue from net sales of Kapruvia; and (5) clinical compound sales from certain license agreements. As of December 31, 2023, the Company has not earned any sales-based milestones under its collaboration agreements.

As of December 31, 2023, the Company had license and collaboration agreements with CSL Vifor, Maruishi and CKDP. The following table provides amounts included in the Company’s Consolidated Statements of Comprehensive Loss as revenue for the years ended December 31, 2023, 2022 and 2021:

<div align='center'>F-68</div>

TABLE OF CONTENTS

CARA THERAPEUTICS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)

| ​                                            
 ​                                            | ​ 
 ​ | ​ 
 ​ | Year Ended December 31, 
 2023                    |   |        |   | ​ | ​ | 2022 |   |        |   | ​ | ​ | 2021 |   |        |   | ​ 
 ​ |
|:---------------------------------------------|:--|:--|:------------------------|:--|-------:|:--|:--|:--|:-----|:--|-------:|:--|:--|:--|:-----|:--|-------:|:--|:--|
| Collaborative revenue                        | ​ | ​ | ​                       | ​ |      ​ | ​ | ​ | ​ | ​    | ​ |      ​ | ​ | ​ | ​ | ​    | ​ |      ​ | ​ | ​ |
| CSL Vifor (KORSUVA injection profit sharing) | ​ | ​ | ​                       | $ | 12,397 | ​ | ​ | ​ | ​    | $ | 16,572 | ​ | ​ | ​ | ​    | $ |      — | ​ | ​ |
| Maruishi                                     | ​ | ​ | ​                       | ​ |    539 | ​ | ​ | ​ | ​    | ​ |      — | ​ | ​ | ​ | ​    | ​ |    706 | ​ | ​ |
| Total collaborative revenue                  | ​ | ​ | ​                       | $ | 12,936 | ​ | ​ | ​ | ​    | $ | 16,572 | ​ | ​ | ​ | ​    | $ |    706 | ​ | ​ |
|